Transmedics Group, Inc. (TMDX) Stock Price & Analysis
Transmedics Group, Inc. (TMDX) rose 1.59% to USD 72.26 as of July 25, 2026 at 10:02 UTC, according to Nexqual real-time market data.
TMDX last closed at USD 71.13; the session ranged USD 68.8–73.86 on volume of 1,139,015 shares. Market capitalization is $2.50B, with a 52-week range of USD 60.11–156 (NGM). Source: Nexqual, July 25, 2026 at 10:02 UTC.
Key Statistics (as of July 25, 2026 at 10:02 UTC)
| Price | USD 72.26 |
|---|---|
| Change | ▲ 1.59% (up) |
| Previous Close | USD 71.13 |
| Open | USD 72.38 |
| Day Range | USD 68.8 – 73.86 |
| 52-Week Range | USD 60.11 – 156 |
| Volume | 1,139,015 shares |
| Market Cap | $2.50B |
| Exchange | NGM |
Technical Analysis (TMDX)
Nexqual's technical model rates TMDX "NEUTRAL" based on 2 bullish and 3 bearish signals across 125 daily candles, as of July 25, 2026 at 10:02 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 51.41 (neutral) |
| vs SMA50 | Above (USD 71.19) |
| MACD | -0.24 (negative) |
Analyst Ratings (TMDX)
Wall Street analysts rate TMDX "Buy" based on 9 analysts, with a mean price target of USD 112.89 (range USD 80–142), per Nexqual as of July 25, 2026 at 10:02 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 112.89 |
| High Target | USD 142 |
| Low Target | USD 80 |
| Buy / Hold / Sell | 7 / 3 / 0 |
Earnings (TMDX)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD 0.47 |
| Revenue Estimate | $183.78M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.3 vs est 0.61 ▼ miss |
| 2025-12-31 | USD 0.53 vs est 0.37 ▲ beat |
| 2025-09-30 | USD 0.66 vs est 0.36 ▲ beat |
| 2025-06-30 | USD 0.92 vs est 0.43 ▲ beat |
Source: Nexqual, July 25, 2026 at 10:02 UTC.
Financials & Fundamentals (TMDX)
| Total Revenue | $635.89M |
|---|---|
| Revenue Growth (YoY) | +21.20% |
| Gross Margin | +59.09% |
| Operating Margin | +7.65% |
| Profit Margin | +27.04% |
| ROE | +45.22% |
| Debt / Equity | 174.78 |
| Current Ratio | 6.74 |
| Total Cash | $461.74M |
| Total Debt | $863.41M |
| Free Cash Flow | $108.82M |
Source: Nexqual, July 25, 2026 at 10:02 UTC.
Financial Health Score (TMDX)
Nexqual rates Transmedics Group, Inc.'s overall financial health "Solid" across five dimensions, as of July 25, 2026 at 10:02 UTC.
| Growth | Strong — Revenue +37% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 59%, operating 8% |
| Balance Sheet | Weak — $462M cash vs $863M debt |
| Cash Flow | Strong — FCF $109M, 18% margin |
| Efficiency | Strong — ROE 45%, ROA 5.2% |
Ownership (TMDX)
| Insider Ownership | +3.65% |
|---|---|
| Institutional Ownership | +109.68% |
| Shares Outstanding | 34.56M |
| Float | 33.43M |
| Short % of Float | +34.82% |
Source: Nexqual, July 25, 2026 at 10:02 UTC.
Leadership (TMDX)
Transmedics Group, Inc. is led by Waleed H. Hassanein (age 57), Founder, President, CEO & Director, per Nexqual as of July 25, 2026 at 10:02 UTC.
| Founder, President, CEO & Director | Waleed H. Hassanein (age 57) |
|---|---|
| CFO & Treasurer | Gerardo Hernandez (age 54) |
| Senior Vice President of Supply Chain & Operations | Nicholas Corcoran (age 43) |
| Senior Vice President of International | Tamer I. Khayal (age 56) |
| Vice President of Global Regulatory Affairs | Miriam C. Provost (age 64) |
Major Backers & Investors (TMDX)
Notable institutional backers of Transmedics Group, Inc. include FMR, LLC, Fidelity, Invesco, according to Nexqual as of July 25, 2026 at 10:02 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.75% |
| Fidelity | 3.58% |
| Invesco | 3% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2.72% |
| Nomura Asset Management International Inc | 2.56% |
| Goldman Sachs | 2.51% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 23.64% |
| Vanguard Group | 16.22% |
| State Street | 3.82% |
| Geode Capital | 2.43% |
Source: Nexqual, July 25, 2026 at 10:02 UTC.
From Transmedics Group, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
- The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
- Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers.
- The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OSCR | Oscar Health, Inc. | USD 28.19 | ▼ 4.44% |
| CELH | Celsius Holdings, Inc. | USD 27.12 | ▼ 4.74% |
| FOUR | Shift4 Payments, Inc. | USD 48.35 | ▲ 0.27% |
| CLPT | ClearPoint Neuro Inc. | USD 14.12 | ▼ 6.05% |
| DLO | DLocal Limited | USD 14.49 | ▲ 1.61% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 10:02 UTC. This page is informational and not investment advice.